Beaujean F, Bernaudin F, Kuentz M, Lemerle S, Cordonnier C, Le Forestier C, Reinert P, Duedari N, Brandely M, Vernant J P
FNTS ATR/CDTS 94, Créteil, France.
Bone Marrow Transplant. 1995 May;15(5):691-6.
Disease recurrence remains the major problem in autologous bone marrow transplantation (BMT) for hematologic malignancies. To improve the therapeutic efficiency of autologous BMT, we investigated the use of autologous marrow activated in vitro with interleukin 2 (IL-2) to generate killer cells for in vivo purging. A feasibility trial was initiated in 5 patients with poor prognosis acute lymphoblastic leukemia, who were transplanted, after marrow ablative therapy, with autologous marrow cultured for 10 days with 10(3) units of IL-2/ml. A highly significant increase in NK activity and an induction of LAK activity were observed after incubation. Patients received 0.64 to 1.56 X 10(8) cultured BM cells/kg and 1.87 to 44.8 x 10(4) CFU-GM/kg. Four patients engrafted and achieved granulocyte counts > 0.5 x 10(9)/l on days 35, 24, 36 and 22 after transplant. Three of these patients showed platelet recovery to > 50 x10(9)/l on days 25, 42 and 40 after transplant. One patient remained thrombocytopenic until relapse. One patient died on day 12 after transplant. This study demonstrates that cultured BM activated with IL-2 can be used successfully for hematological rescue in the clinical setting.
疾病复发仍然是血液系统恶性肿瘤自体骨髓移植（BMT）中的主要问题。为提高自体BMT的治疗效果，我们研究了使用经白细胞介素2（IL-2）体外激活的自体骨髓来产生杀伤细胞进行体内净化。对5例预后不良的急性淋巴细胞白血病患者启动了一项可行性试验，这些患者在骨髓清除疗法后，接受了用10³单位IL-2/ml培养10天的自体骨髓移植。培养后观察到NK活性显著增强以及LAK活性被诱导。患者接受了0.64至1.56×10⁸个培养的骨髓细胞/kg和1.87至44.8×10⁴个CFU-GM/kg。4例患者移植后第35、24、36和22天粒细胞计数>0.5×10⁹/l。其中3例患者移植后第25、42和40天血小板恢复至>50×10⁹/l。1例患者直至复发时仍血小板减少。1例患者移植后第12天死亡。本研究表明，用IL-2激活的培养骨髓在临床环境中可成功用于血液学救援。
